Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2050166 | 0.85 | HDAC1 (0.31) | HDAC1HDAC2LMNA | |
| SCHEMBL43414 | 0.81 | POLB (0.41) | POLBHDAC1HDAC2NPC1RAB9A | |
| SCHEMBL342420 | 0.80 | POLB (0.45) | POLBHDAC1HDAC2NPC1RAB9A | |
| SCHEMBL18084525 | 0.79 | EHMT2 (0.36) | POLBNPC1RAB9AALDH1A1MAPT | |
| SCHEMBL18726574 | 0.79 | HDAC1 (0.37) | HDAC1HDAC2NPC1RAB9AALDH1A1 | |
| SCHEMBL29353376 | 0.79 | HDAC1 (0.37) | HDAC1HDAC2NPC1RAB9AALDH1A1 | |
| SCHEMBL574827 | 0.79 | HDAC1 (0.37) | HDAC1HDAC2NPC1RAB9AALDH1A1 | |
| SCHEMBL2435515 | 0.78 | POLB (0.41) | POLBHDAC1HDAC2NPC1RAB9A | |
| SCHEMBL18726765 | 0.77 | HDAC1 (0.40) | HDAC1HDAC2ALDH1A1LMNA | |
| SCHEMBL9904994 | 0.73 | HDAC1 (0.36) | HDAC1HDAC2ALDH1A1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846080-B2 | Vaccine | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2014-09-30 | — | — | US | disclosed |
| US-20110159081-A1 | VACCINE | GLAXOSMITHKLINE BIOLOGICALS S.A. | 2011-06-30 | — | — | US | disclosed |
| WO-2003104424-A2 | NOVEL MOLECULAR CONJUGATES FOR SIGNAL AMPLIFICATION | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110159081-A1 | VACCINE | LY96, CD47, CD74 | POLB 3385/4885HDAC1 2639/4885HDAC2 2838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.